Exploratory single-gene analysis of the MAGNITUDE trial, although underpowered, showed potential benefit of combined PARP and androgen receptor inhibition in patients with a Fanconi anemia pathway gene alteration (PALB2, BRIP1 and FANCA) beyond BRCA1/BRCA2 (ref. 34), whereas a lack of differential benefit was seen in tumors with CDK12 alterations34. Here, FANCA is linked to Fanconi anemia.